ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 891,68
0,00%
Dow Jones
44 873,28
0,71%
DAX
21 585,93
0,35%
Brent Oil
74,64
0,08%
Bitcoin
98 313,01
1,75%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Italie
  5. BIT

  6. Philogen Spa (PHIL) Cours

Philogen Spa

Philogen Spa (PHIL)

Pacific Horizon Investment Trust PLC
Pacific Horizon Investment Trust PLC
Pacific Horizon Investment Trust PLC
PHI Group Inc (PK)
18,40
0,00
(0,00%)
Fermé 06 Février 5:30PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
18,40
Prix Achat
17,70
Prix Vente
18,45
Volume échangé
0,00
0,00 Fourchette du Jour 0,00
16,30 Plage de 52 semaines 21,90
Cap du marché
743,316M
Clôture Veille
18,40
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
6 332
Actions en circulation
40 397 605
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-
Chiffre d'affairess
25,12M
Bénéfice net
-6,16M

À propos de Philogen Spa

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.philogen.com
Siège social
Siena, Siena, Ita
Fondé
-
Philogen Spa est coté dans le secteur Pharmaceutical Preparations de la Italian Stock Exchange avec le ticker PHIL. Le dernier cours de clôture d'Philogen était de 18,40 €. Au cours de la dernière année, les actions de Philogen ont été négociées dans une fourchette de prix de 16,30 € à 21,90 €.

Philogen compte actuellement 40 397 605 actions en circulation. La capitalisation boursière d'Philogen est de 743,32 € million.

PHIL Dernières nouvelles

Plus de nouvelles

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue...

20 Février 2024
GlobeNewswire Inc.

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities SIENA, Italy, Dec. 05, 2023...

05 Décembre 2023
GlobeNewswire Inc.

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors Novel...

04 Décembre 2023
GlobeNewswire Inc.

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial...

16 Octobre 2023
GlobeNewswire Inc.

Philogen Announces Clinical Trial Collaboration with MSD

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with...

01 Juin 2023
GlobeNewswire Inc.

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand Mumbai...

30 Mai 2023
GlobeNewswire Inc.

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich Philogen Publishes New Data on a...

25 Mai 2023
GlobeNewswire Inc.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology Philogen Announces Publication...

28 Mars 2023
GlobeNewswire Inc.

Philogen Provides Corporate Update

Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows potent activity in last-line glioblastoma in...

01 Décembre 2022
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.42.222222222221818.7516.51260017.35371752DE
4-0.45-2.3872679045118.8518.916.5686917.84195456DE
12-1.55-7.769423558919.9520.116.5633218.67357316DE
26-2.3-11.111111111120.721.916.5681919.63497336DE
521.26.9767441860517.221.916.3853819.12031177DE
156427.777777777814.421.913858416.96908882DE
2601.48.235294117651721.912.61197816.04539115DE

PHIL - Frequently Asked Questions (FAQ)

What is the current Philogen share price?
The current share price of Philogen is 18,40 €
How many Philogen shares are in issue?
Philogen has 40 397 605 shares in issue
What is the market cap of Philogen?
The market capitalisation of Philogen is EUR 743,32M
What is the 1 year trading range for Philogen share price?
Philogen has traded in the range of 16,30 € to 21,90 € during the past year
What is the reporting currency for Philogen?
Philogen reports financial results in EUR
What is the latest annual turnover for Philogen?
The latest annual turnover of Philogen is EUR 25,12M
What is the latest annual profit for Philogen?
The latest annual profit of Philogen is EUR -6,16M
What is the registered address of Philogen?
The registered address for Philogen is PIAZZA LA LIZZA, 7, SIENA, SIENA, 53100
What is the Philogen website address?
The website address for Philogen is www.philogen.com
Which industry sector does Philogen operate in?
Philogen operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
1AAAlcoa Corp
34,20 €
(0,00%)
0
1AAgilent Technologies Inc
125,32 €
(0,00%)
0
19MWMarvell Technology Inc
110,12 €
(0,00%)
0
18TRATraton SE
29,25 €
(0,00%)
0
11COVBearer Shares
55,76 €
(0,00%)
0
1AAAlcoa Corp
34,20 €
(0,00%)
0
1AAgilent Technologies Inc
125,32 €
(0,00%)
0
19MWMarvell Technology Inc
110,12 €
(0,00%)
0
18TRATraton SE
29,25 €
(0,00%)
0
11COVBearer Shares
55,76 €
(0,00%)
0
1AAAlcoa Corp
34,20 €
(0,00%)
0
1AAgilent Technologies Inc
125,32 €
(0,00%)
0
19MWMarvell Technology Inc
110,12 €
(0,00%)
0
18TRATraton SE
29,25 €
(0,00%)
0
11COVBearer Shares
55,76 €
(0,00%)
0

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

BIT
PHIL
Philogen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces